Amivantamab demonstrates multifaceted activity by inhibiting the signaling of EGFR and MET, which has a high affinity for hepatocyte growth factor (HGF), both cell surface receptors involved in regulating cell growth, survival, and differentiation, through various mechanisms, suggesting significant therapeutic potential in the treatment of cancers associated with these signaling pathways [10]. This evidence concerns the gene EGFR and cancer.